ALT flares were linked to HBsAg reduction, seroclearance and seroconversion: interim results from a phase IIb study in chronic hepatitis B patients with 24-week treatment of subcutaneous PD-L1 Ab ASC22 (Envafolimab) plus nucleos (t)ide analogs
JOURNAL OF HEPATOLOGY(2022)
摘要
ALT) levels throughout the study; 2 participants in each regimen had grade 1 ALT elevations.No treatment-related serious AEs were reported. Conclusion:These preliminary data support that a longer duration of treatment with VIR-2218 results in deeper and more sustained reductions in HBsAg.In both regimens of VIR-2218, no differences in safety or tolerability were observed.
更多查看译文
关键词
chronic hepatitis,hbsag reduction
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要